| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yang Yao | |
| Zan Shen | |||
| Li-Na Tang | |||
| Wei-Xiang Qi | |||
| P2860 | cites work | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials | Q26822790 |
| Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis | Q27026453 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. | Q30492863 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial | Q33385435 | ||
| Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study | Q33386535 | ||
| Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial | Q33408323 | ||
| Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer | Q33409885 | ||
| Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | Q33417933 | ||
| Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer | Q33794403 | ||
| Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. | Q33887946 | ||
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | Q34163515 | ||
| Sunitinib in patients with metastatic renal cell carcinoma | Q34568166 | ||
| Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study | Q34584163 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Q34638316 | ||
| Cediranib for metastatic alveolar soft part sarcoma | Q34651131 | ||
| Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials | Q34900938 | ||
| Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications | Q35040017 | ||
| Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload | Q35095396 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. | Q36514752 | ||
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
| Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials | Q36729895 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 | ||
| Phase II trial of sorafenib in advanced thyroid cancer | Q37121708 | ||
| Phase II trial of sorafenib in metastatic thyroid cancer | Q37158278 | ||
| Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis | Q37161889 | ||
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 | ||
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. | Q37278365 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | Q37501707 | ||
| Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37600496 | ||
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 | ||
| Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 | ||
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 | ||
| Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis | Q38014986 | ||
| Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. | Q38144490 | ||
| Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis | Q38158401 | ||
| Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. | Q38177768 | ||
| Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. | Q38184936 | ||
| Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study | Q39090350 | ||
| Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. | Q39514813 | ||
| Activity of sunitinib in patients with advanced neuroendocrine tumors | Q39963579 | ||
| Phase II study of sunitinib in men with advanced prostate cancer. | Q39983597 | ||
| Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma | Q42672244 | ||
| Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | Q43272859 | ||
| A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. | Q43279004 | ||
| Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma | Q43299262 | ||
| Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma | Q43299263 | ||
| Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer | Q43299267 | ||
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study | Q43679835 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial | Q44226532 | ||
| Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. | Q44741318 | ||
| A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer | Q45812913 | ||
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma | Q46837791 | ||
| Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy | Q46942058 | ||
| Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. | Q51435694 | ||
| Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. | Q53087417 | ||
| First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. | Q54529978 | ||
| Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials | Q71020165 | ||
| Heterogeneity testing in meta-analysis of genome searches | Q81128804 | ||
| Microvascular plasticity and experimental heart failure | Q82984828 | ||
| Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor | Q85062672 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| heart failure | Q181754 | ||
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 748-762 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials | |
| P478 | volume | 78 |
| Q57057499 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines |
| Q42359608 | Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis |
| Q52808495 | Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. |
| Q38237318 | Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups |
| Q38625034 | Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer |
| Q89160743 | Cardiotoxicity of Novel Targeted Chemotherapeutic Agents |
| Q39103481 | Cardiovascular disease in cancer survivors |
| Q38612008 | Drug safety evaluation of lenvatinib for thyroid cancer. |
| Q38843403 | Efficacy of lenvatinib in treating thyroid cancer. |
| Q36024704 | Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis |
| Q38260495 | Novel therapies for thyroid cancer |
| Q47367575 | Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. |
| Q36027042 | Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours |
| Q64996518 | Reversible Left Ventricular Systolic Dysfunction Secondary to Pazopanib. |
| Q37042424 | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review |
| Q26752891 | Selective use of sorafenib in the treatment of thyroid cancer |
| Q38326036 | Sorafenib for the treatment of thyroid cancer: an updated review. |
| Q53662662 | Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle. |
| Q64103972 | Surviving Cancer without a Broken Heart |
| Q49328959 | Targeted Therapy for Medullary Thyroid Cancer: A Review |
| Q87659774 | The Future Role of Cardio-oncologists |
| Q52715902 | The Impact of Pazopanib on the Cardiovascular System. |
| Q90481482 | Therapeutic ultrasound combined with microbubbles improves atherosclerotic plaque stability by selectively destroying the intraplaque neovasculature |
| Q38501976 | Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit |
Search more.